Home » Healthcare » Pharmaceuticals » Opioid Drugs Market

Opioid Drugs Market By Drug Class (Morphine, Methadone, Codeine, Oxycodone, Meperidine, Fentanyl, Other Opioid Drugs); By Application (Pain Management, Cough Suppressant, Diarrhea, Anesthesia); By Sales Channel (Retail Pharmacies, Hospital Pharmacies, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: Opioid Drugs Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-10-27
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Opioid Drugs Market

Summary
Table Of Content
Request Free Sample

Market Overview:

The Global Opioid Drugs Market size was valued at USD 15,712.5 million in 2018 to USD 22,518.0 million in 2024 and is anticipated to reach USD 38,293.0 million by 2032, at a CAGR of 6.92% during the forecast period.

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Opioid Drugs Market Size 2024	USD 22,518.0 million
Opioid Drugs Market, CAGR	6.92%
Opioid Drugs Market Size 2032	USD 38,293.0 million

The Global Opioid Drugs Market is driven by the rising incidence of chronic pain, post-surgical recovery needs, and increasing palliative care demand. Expanding awareness of effective pain management solutions among healthcare providers strengthens market growth. Technological advancements in drug formulation aimed at reducing addiction risk and improving patient compliance further support adoption across therapeutic settings, especially in oncology, orthopedics, and trauma care.

North America leads the market due to high prescription volumes, advanced healthcare systems, and established pharmaceutical networks. Europe follows, supported by strong healthcare infrastructure and the increasing prevalence of chronic illnesses. The Asia-Pacific region is emerging rapidly, driven by rising healthcare access, a growing elderly population, and government efforts to expand pain management therapies in developing nations.

Opioid Drugs Market size

Market Insights:

The Global Opioid Drugs Market size was valued at USD 15,712.5 million in 2018, reached USD 23,964.73 million in 2024, and is projected to attain USD 38,292.97 million by 2032, growing at a CAGR of 6.92% during the forecast period.
North America (32%), Europe (26%), and Asia Pacific (27%) accounted for the largest market shares in 2024 due to high prescription rates, advanced healthcare infrastructure, and strong adoption of pain management therapies across clinical applications.
Asia Pacific is the fastest-growing region with a 31% share, driven by expanding healthcare access, increasing cancer prevalence, and government support for palliative care and pain treatment initiatives.
Retail pharmacies captured about 46% of the market share, supported by high outpatient prescription volumes and wider drug accessibility for chronic pain patients.
Hospital pharmacies held nearly 42% share, driven by strong demand for controlled opioid distribution in surgical and inpatient care, while the “others” segment accounted for the remaining 12%, reflecting specialty and online distribution growth.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Drivers:

Rising Prevalence of Chronic and Postoperative Pain Disorders

The Global Opioid Drugs Market is driven by increasing incidences of chronic pain disorders and postoperative pain management needs. Conditions such as cancer, arthritis, neuropathy, and lower back pain continue to fuel prescription rates. The growing aging population further contributes to long-term pain management demand. Opioid-based therapies offer fast and effective relief, promoting wider clinical adoption. Hospitals and pain clinics increasingly rely on these drugs to maintain patient comfort and recovery outcomes. Expanding surgical volumes globally strengthen their demand in acute care settings. The continuous rise in lifestyle-related disorders enhances the dependence on effective analgesic solutions. This trend keeps the need for advanced opioid formulations strong across medical institutions.

For example, a 2020 study analyzing hip and knee arthroplasty encounters found that patients who received lower post-operative morphine milligram equivalents (MME) per day had a shorter median LOS. Furthermore, implementing proper medication reconciliation, particularly when led by pharmacists, has been shown to reduce medication errors, which can improve patient safety and potentially contribute to better outcomes.

Growing Demand for Effective Palliative and Cancer Pain Management

Strong demand for palliative care and oncology-related pain treatment supports the market’s expansion. Opioid drugs are considered essential for end-of-life and cancer care due to their efficacy in managing severe pain. Rising global cancer cases push healthcare providers to adopt these drugs for symptom relief. Clinical guidelines from global health authorities emphasize opioid use for terminal illness management. Increasing awareness about patient-centered care encourages regulated use among medical professionals. Many hospitals now include opioids in their multidisciplinary pain management programs. Pharmaceutical firms continue to invest in safer formulations with lower addiction potential. These developments enhance therapeutic reliability and ensure wider accessibility.

For instance, Mundipharma’s oxycodone/naloxone combination therapy has been confirmed through clinical studies to provide non-inferior pain control in cancer patients with a similar incidence of adverse drug reactions compared to traditional oxycodone controlled release in a large Korean trial sponsored by Mundipharma Korea Ltd.

Technological Advances in Drug Delivery and Formulation Innovation

Innovation in drug delivery systems enhances safety and dosage precision in opioid therapy. Extended-release, abuse-deterrent, and transdermal formulations are gaining strong traction. These technologies help minimize misuse while ensuring consistent pain relief. Pharmaceutical companies are adopting advanced polymer and encapsulation technologies for sustained release. Digital platforms and e-prescriptions support safe distribution and patient tracking. Such progress improves therapeutic control and optimizes patient adherence. The focus on precision dosing reduces side effects, promoting confidence among prescribers. These improvements create a favorable outlook for the Global Opioid Drugs Market across medical disciplines.

Rising Healthcare Expenditure and Expanding Access to Pain Therapies

Increasing healthcare spending and insurance coverage in both developed and emerging countries support the wider use of opioids. Many governments are including essential pain medicines in public health programs. Expanding hospital infrastructure and specialized pain centers strengthen drug accessibility. Economic development in Asia-Pacific and Latin America boosts demand for advanced pain relief drugs. Growing focus on quality of life improvement among patients reinforces therapeutic adoption. Improved availability of generic opioids increases treatment affordability. Educational campaigns promoting responsible opioid use enhance prescribing confidence. Together, these factors sustain market growth and encourage regional expansion.

Market Trends:

Shift Toward Abuse-Deterrent and Safer Formulations

Manufacturers are developing next-generation opioid formulations designed to deter misuse and overdose. These abuse-deterrent products use physical and chemical barriers that prevent tampering and inhalation. The approach aligns with global efforts to reduce opioid dependency. Demand for such products is strong in the United States and Europe due to regulatory encouragement. Pharmaceutical innovations combine effective pain control with controlled-release mechanisms. Research is focusing on minimizing euphoria while maintaining analgesic efficacy. This evolution helps restore clinical trust and balance safety with patient comfort. It reflects a long-term shift in the Global Opioid Drugs Market toward responsible innovation.

For instance, after Purdue Pharma’s launch of its hardened OxyContin abuse-deterrent formulation, national surveys indicated a steep decline in tampering and abuse for injected or inhaled routes in the first 12-18 months, supporting FDA labeling recognition for the deterrent effect.

Increasing Integration of Non-Opioid Alternatives with Opioid Therapy

Healthcare systems are exploring combination approaches that merge opioids with non-opioid pain management strategies. Multimodal therapy is gaining favor to reduce dosage requirements and mitigate addiction risk. Hospitals and pain centers now combine behavioral therapy, physical therapy, and regional anesthesia. This integration helps optimize outcomes in chronic pain treatment. Pharmaceutical collaborations are emerging to develop fixed-dose combination products. Physicians prefer these strategies to reduce dependency rates without compromising pain relief. The growing focus on personalized treatment enhances patient monitoring and safety. These shifts reflect a transformation in therapeutic philosophy toward balanced pain management.

For instance, randomized pilot trials found that office-based buprenorphine maintenance combined with web-delivered cognitive-behavioral therapy achieved a urine toxicology screening rate negative for opioids of 91%, versus 64% with standard buprenorphine alone, indicating significant improvement in patient safety and reduced drug use.

Digital Health Tools Supporting Prescriber Monitoring and Patient Safety

Digitalization plays a growing role in opioid therapy management. Governments and health institutions are implementing electronic prescription monitoring programs to prevent misuse. Healthcare providers use digital records to track patient behavior and ensure safe dispensing. Remote patient monitoring systems enable real-time evaluation of pain management effectiveness. Artificial intelligence assists in identifying prescription anomalies and reducing overuse. Telemedicine platforms also streamline consultations and controlled prescriptions. Integration of data analytics improves regulatory compliance and patient care. The Global Opioid Drugs Market benefits from digital oversight systems that build accountability and transparency.

Rising Emphasis on Patient Education and Responsible Usage Programs

Public health authorities and pharmaceutical firms are promoting awareness about responsible opioid consumption. Educational campaigns inform patients about proper dosage, disposal, and potential side effects. Medical associations collaborate with governments to create safer prescription frameworks. Healthcare professionals are trained to identify early signs of dependency. This awareness reduces the stigma around legitimate opioid use for pain relief. Many regions are launching patient support programs that include counseling and monitoring. Community-level outreach is improving treatment adherence and public perception. These initiatives strengthen patient trust and stabilize long-term market sustainability.

Market Challenges Analysis:

Growing Concerns About Addiction, Misuse, and Regulatory Restrictions

The Global Opioid Drugs Market faces significant pressure from the risk of misuse and addiction. Rising opioid-related fatalities have led to strict regulations in many countries. Government agencies have tightened approval procedures and imposed prescription limits. These restrictions affect sales growth and prescribing patterns across hospitals and pharmacies. Healthcare professionals are cautious about long-term opioid therapy due to dependency risks. Pharmaceutical companies face increasing compliance costs to meet safety requirements. Public scrutiny of opioid use impacts the reputation of drug manufacturers. This environment challenges market expansion and encourages a shift toward alternative pain therapies.

Supply Chain Disruptions and Dependence on Controlled Substances

The production and distribution of opioids rely heavily on controlled raw materials subject to strict monitoring. Supply disruptions due to geopolitical tensions, regulatory checks, or transportation delays affect drug availability. Manufacturers face difficulties maintaining consistent inventory under strict compliance conditions. Limited access to high-quality active ingredients in developing countries slows growth. Governments impose complex documentation and approval systems for imports and exports. These factors reduce production efficiency and discourage smaller manufacturers. The industry must adopt resilient sourcing models to maintain stable supply. This challenge continues to shape operational strategies across the pharmaceutical landscape.

Market Opportunities:

Expansion in Emerging Healthcare Markets and Untapped Regions

The Global Opioid Drugs Market offers strong potential in emerging economies with growing healthcare access. Rising hospital infrastructure and improved insurance coverage enable greater treatment penetration. Countries in Asia-Pacific, Latin America, and the Middle East are expanding pain management programs. Healthcare reforms are creating favorable environments for pharmaceutical investments. Increased disease awareness encourages physicians to adopt modern pain relief drugs. Collaborations with local manufacturers improve drug availability in underserved areas. Expanding retail pharmacy networks also boost accessibility for outpatients. These dynamics create new growth avenues for global players.

R&D Investments in Safer and Non-Addictive Opioid Alternatives

Research is intensifying to develop opioids with minimal risk of dependency and abuse. Pharmaceutical companies are testing receptor-specific molecules that deliver pain relief without triggering addiction pathways. Partnerships between biotech firms and academic institutions accelerate innovation. These efforts aim to restore clinical confidence and regulatory support for opioid use. Emerging technologies like nanocarrier systems enhance precision in drug delivery. Companies investing in these solutions can capture long-term market advantages. The trend positions innovation as the key growth driver for the next decade. Such research diversification strengthens sustainability in the evolving therapeutic landscape.

Market Segmentation Analysis:

By Drug Class

The Global Opioid Drugs Market is segmented by drug class into morphine, methadone, codeine, oxycodone, meperidine, fentanyl, and other opioid drugs. Morphine dominates due to its effectiveness in managing severe and chronic pain. Fentanyl is rapidly expanding because of its potency and controlled-release forms used in surgical and palliative care. Oxycodone and methadone maintain significant market shares owing to their wide prescription in moderate to severe pain therapy. Demand for codeine remains stable in mild pain and cough formulations, while meperidine use declines due to side-effect concerns. Emerging formulations within this category focus on abuse deterrence and safer dosing profiles.

For instance, injectable morphine commanded 45.52% of global hospital market share in 2024 due to rapid onset, while extended-release morphine formulations with abuse-deterrent layers showed the fastest uptake at 9.35% CAGR, demonstrating the technology’s traction in hospital pain management.

By Application

The market is classified by application into pain management, cough suppressant, diarrhea, and anesthesia. Pain management leads the segment with high adoption in cancer, orthopedic, and postoperative treatment. Opioids remain essential in palliative care for terminal illness pain relief. The anesthesia segment shows steady growth in surgical applications requiring rapid analgesia. The cough suppressant and diarrhea segments sustain demand in combination therapies where opioid derivatives provide secondary therapeutic effects.

For instance, the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), following a review by the European Medicines Agency (EMA), adopted measures on April 22, 2015, which prohibited the use of codeine-containing medicines for cough and cold in children under 12 years of age. The measures also included warnings for adolescents and others with breathing problems, as well as breastfeeding women.

By Sales Channel

By distribution, the market is divided into retail pharmacies, hospital pharmacies, and others. Hospital pharmacies dominate due to higher inpatient and postoperative usage. Retail pharmacies serve long-term pain patients requiring chronic medication support. Online and specialty outlets in the “others” category are expanding with regulatory approvals for controlled distribution.

Opioid Drugs Market segmentation

Segmentation:

By Drug Class:

Morphine
Methadone
Codeine
Oxycodone
Meperidine
Fentanyl
Other Opioid Drugs

By Application:

Pain Management
Cough Suppressant
Diarrhea
Anesthesia

By Sales Channel:

Retail Pharmacies
Hospital Pharmacies
Others

By Region:

North America
- U.S.
- Canada
Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa

Regional Analysis:

North America

The North America Global Opioid Drugs Market size was valued at USD 5,188.28 million in 2018 to USD 7,345.68 million in 2024 and is anticipated to reach USD 12,288.22 million by 2032, at a CAGR of 6.7% during the forecast period. North America holds the largest market share of 32% in the Global Opioid Drugs Market. The region’s dominance is supported by high prescription rates, advanced healthcare infrastructure, and strong availability of pain management drugs. The U.S. remains the key contributor due to its established pharmaceutical industry and large patient base requiring chronic pain therapy. Strong regulatory frameworks drive innovation in abuse-deterrent formulations to reduce misuse. Canada and Mexico are expanding their palliative care programs, increasing opioid accessibility in controlled environments. Ongoing efforts to balance pain relief with public health safety shape the region’s future growth. Increasing government monitoring and education programs support safer prescription practices.

Europe

The Europe Global Opioid Drugs Market size was valued at USD 3,893.57 million in 2018 to USD 5,676.45 million in 2024 and is anticipated to reach USD 9,871.93 million by 2032, at a CAGR of 7.2% during the forecast period. Europe accounts for a 26% market share and continues to experience steady growth. High prevalence of chronic pain disorders, an aging population, and expanding use in cancer care drive the regional demand. The UK, Germany, and France dominate due to their advanced healthcare systems and established regulatory oversight. Strong adoption of pain management protocols across hospitals supports consistent prescription volumes. Pharmaceutical companies focus on research partnerships to develop safer, extended-release opioids. Eastern European countries are catching up through healthcare modernization and improved drug availability. Rising awareness about palliative and end-of-life care expands market penetration. It benefits from policy initiatives promoting responsible and evidence-based opioid use.

Asia Pacific

The Asia Pacific Global Opioid Drugs Market size was valued at USD 4,135.54 million in 2018 to USD 5,974.98 million in 2024 and is anticipated to reach USD 10,270.18 million by 2032, at a CAGR of 7.1% during the forecast period. Asia Pacific holds a 27% share, making it the fastest-growing regional market. Increasing healthcare investments and expanding hospital networks are improving patient access to opioid therapies. Rising incidence of chronic diseases such as cancer and arthritis fuels demand for effective pain management. China, Japan, and India lead the regional landscape with strong local production and evolving regulatory policies. Governments are promoting palliative care programs and physician education to ensure safe prescribing. Adoption of controlled-release and non-addictive formulations is rising across hospitals and clinics. Rapid urbanization and improved insurance systems support market penetration. Growing collaborations between global and local pharmaceutical firms further enhance regional growth.

Latin America

The Latin America Global Opioid Drugs Market size was valued at USD 1,150.16 million in 2018 to USD 1,606.82 million in 2024 and is anticipated to reach USD 2,638.39 million by 2032, at a CAGR of 6.5% during the forecast period. Latin America contributes to 7% of the global market share. Growth is supported by improving healthcare infrastructure and increasing access to advanced pain management therapies. Brazil remains the largest market due to its expanding pharmaceutical manufacturing and cancer treatment facilities. Argentina and Chile are witnessing higher adoption rates in hospital-based pain management. Regional governments are implementing regulatory reforms to balance accessibility with safety. Growing awareness of opioid therapy among healthcare professionals supports market development. Economic stability in certain countries strengthens pharmaceutical import and distribution systems. Strategic alliances with international drug manufacturers are improving availability across the region.

Middle East

The Middle East Global Opioid Drugs Market size was valued at USD 908.18 million in 2018 to USD 1,305.40 million in 2024 and is anticipated to reach USD 2,228.65 million by 2032, at a CAGR of 7.0% during the forecast period. The region accounts for 5% of the global share, showing gradual adoption of opioid-based treatments. Demand growth is driven by increasing surgical procedures, palliative care expansion, and improved healthcare accessibility. GCC countries lead the regional landscape with well-structured hospital networks and government-led awareness initiatives. Israel and Turkey are developing local manufacturing capabilities for pain management drugs. Healthcare modernization programs enhance the supply chain efficiency for controlled substances. Strict regulations ensure medical use remains safe and supervised. Rising cancer incidence rates and higher healthcare spending sustain long-term demand. Regional collaboration in medical training strengthens responsible opioid utilization practices.

Africa

The Africa Global Opioid Drugs Market size was valued at USD 436.81 million in 2018 to USD 608.63 million in 2024 and is anticipated to reach USD 995.62 million by 2032, at a CAGR of 6.4% during the forecast period. Africa represents around 3% of the total market share and is in the early stage of adoption. The region’s growth is supported by increasing awareness of pain management in public healthcare systems. South Africa leads the market due to better access to hospitals and pharmaceutical imports. Egypt follows with growing investments in oncology and palliative care infrastructure. Many African nations are introducing reforms to improve access to essential pain medicines. Limited resources and lack of trained professionals remain challenges. Global organizations are supporting initiatives to expand opioid availability for legitimate medical use. With ongoing healthcare improvements, Africa’s role in the Global Opioid Drugs Market is expected to expand steadily.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis:

Purdue Pharma L.P.
Johnson & Johnson Services, Inc.
Hikma Pharmaceuticals PLC
Pfizer Inc.
AbbVie Inc.
Sanofi
Sun Pharmaceutical Industries Ltd
Grünenthal
Merck & Co., Inc.
Insys Therapeutics

Competitive Analysis:

The Global Opioid Drugs Market is moderately consolidated, with major players such as Purdue Pharma, Pfizer, AbbVie, Johnson & Johnson, and Hikma Pharmaceuticals leading through diverse portfolios and global presence. It is driven by continuous R&D investment aimed at developing safer, abuse-deterrent, and extended-release formulations. Companies focus on mergers, licensing deals, and regional expansion to strengthen distribution networks and regulatory compliance. Innovation in non-addictive pain management drugs enhances market competitiveness. Strategic partnerships between pharmaceutical firms and healthcare organizations help broaden patient access and optimize product availability.

Recent Developments:

In October 2025, Purdue Pharma L.P. announced that its Chapter 11 Plan of Reorganization received overwhelming creditor support, marking a significant step toward the company’s reorganization amid ongoing opioid litigation.
In July 2025, Hikma Pharmaceuticals launched Morphine Sulfate Injection, USP, in prefilled syringe formats (2mg/mL and 4mg/mL), developed for pain management where opioid medication is required, with approval for the U.S. market.

Report Coverage:

The research report offers an in-depth analysis based on drug class, application, sales channel, and region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

Demand for safer, abuse-deterrent opioid formulations will grow across developed markets.
Increased investment in R&D will drive innovation in non-addictive pain relief options.
Regulatory reforms will focus on responsible prescription and patient safety.
Growth in palliative care services will boost opioid adoption in chronic pain treatment.
Expanding healthcare infrastructure in emerging economies will open new market opportunities.
Digital health tools and AI-driven monitoring will improve prescription control.
Generic drug manufacturers will strengthen their presence through cost-effective solutions.
Collaboration between pharmaceutical companies and governments will enhance distribution security.
Evolving patient awareness programs will promote responsible opioid consumption.
Innovation in delivery systems, including patches and injectables, will improve treatment outcomes.

CHAPTER NO. 1 : GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2 : EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3 : OPIOID DRUGS MARKET FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown

CHAPTER NO. 4 : KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Product Frontiers – Lucrative Drug Class Categories

4.3 Sales Channel Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Drug Class, Application, and Sales Channel Revenue

CHAPTER NO. 6 : TRADE & COMMERCE ANALYSIS

6.1. Import Analysis By Region

6.1.1. Global Opioid Drugs Market Import Revenue By Region

6.2. Export Analysis By Region

6.2.1. Global Opioid Drugs Market Export Revenue By Region

CHAPTER NO. 7 : COMPETITION ANALYSIS

7.1. Company Market Share Analysis

7.1.1. Global Opioid Drugs Market: Company Market Share

7.2. Global Opioid Drugs Market Company Revenue Market Share

7.3. Strategic Developments

7.3.1. Acquisitions & Mergers

7.3.2. New Product Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8 : OPIOID DRUGS MARKET – BY DRUG CLASS SEGMENT ANALYSIS

8.1. Opioid Drugs Market Overview By Drug Class Segment

8.1.1. Opioid Drugs Market Revenue Share By Drug Class

8.2. Morphine

8.3. Methadone

8.4. Codeine

8.5. Oxycodone

8.6. Meperidine

8.7. Fentanyl

8.8. Other opioid drugs

CHAPTER NO. 9 : OPIOID DRUGS MARKET – BY APPLICATION SEGMENT ANALYSIS

9.1. Opioid Drugs Market Overview By Application Segment

9.1.1. Opioid Drugs Market Revenue Share By Application

9.2. Pain Management

9.3. Cough Suppressant

9.4. Diarrhea

9.5. Anesthesia

CHAPTER NO. 10 : OPIOID DRUGS MARKET – BY SALES CHANNEL SEGMENT ANALYSIS

10.1. Opioid Drugs Market Overview By Sales Channel Segment

10.1.1. Opioid Drugs Market Revenue Share By Sales Channel

10.2. Retail Pharmacies

10.3. Hospital Pharmacies

10.4. Others

CHAPTER NO. 11 : OPIOID DRUGS MARKET – REGIONAL ANALYSIS

11.1. Opioid Drugs Market Overview By Region Segment

11.1.1. Global Opioid Drugs Market Revenue Share By Region

10.1.2. Regions

11.1.3. Global Opioid Drugs Market Revenue By Region

11.1.4. Drug Class

11.1.5. Global Opioid Drugs Market Revenue By Drug Class

11.1.6. Application

11.1.7. Global Opioid Drugs Market Revenue By Application

11.1.8. Sales Channel

11.1.9. Global Opioid Drugs Market Revenue By Sales Channel

CHAPTER NO. 12 : NORTH AMERICA OPIOID DRUGS MARKET – COUNTRY ANALYSIS

12.1. North America Opioid Drugs Market Overview By Country Segment

12.1.1. North America Opioid Drugs Market Revenue Share By Region

12.2. North America

12.2.1. North America Opioid Drugs Market Revenue By Country

12.2.2. Drug Class

12.2.3. North America Opioid Drugs Market Revenue By Drug Class

12.2.4. Application

12.2.5. North America Opioid Drugs Market Revenue By Application

12.2.6. Sales Channel

12.2.7. North America Opioid Drugs Market Revenue By Sales Channel

12.3. U.S.

12.4. Canada

12.5. Mexico

CHAPTER NO. 13 : EUROPE OPIOID DRUGS MARKET – COUNTRY ANALYSIS

13.1. Europe Opioid Drugs Market Overview By Country Segment

13.1.1. Europe Opioid Drugs Market Revenue Share By Region

13.2. Europe

13.2.1. Europe Opioid Drugs Market Revenue By Country

13.2.2. Drug Class

13.2.3. Europe Opioid Drugs Market Revenue By Drug Class

13.2.4. Application

13.2.5. Europe Opioid Drugs Market Revenue By Application

13.2.6. Sales Channel

13.2.7. Europe Opioid Drugs Market Revenue By Sales Channel

13.3. UK

13.4. France

13.5. Germany

13.6. Italy

13.7. Spain

13.8. Russia

13.9. Rest of Europe

CHAPTER NO. 14 : ASIA PACIFIC OPIOID DRUGS MARKET – COUNTRY ANALYSIS

14.1. Asia Pacific Opioid Drugs Market Overview By Country Segment

14.1.1. Asia Pacific Opioid Drugs Market Revenue Share By Region

14.2. Asia Pacific

14.2.1. Asia Pacific Opioid Drugs Market Revenue By Country

14.2.2. Drug Class

14.2.3. Asia Pacific Opioid Drugs Market Revenue By Drug Class

14.2.4. Application

14.2.5. Asia Pacific Opioid Drugs Market Revenue By Application

14.2.6. Sales Channel

14.2.7. Asia Pacific Opioid Drugs Market Revenue By Sales Channel

14.3. China

14.4. Japan

14.5. South Korea

14.6. India

14.7. Australia

14.8. Southeast Asia

14.9. Rest of Asia Pacific

CHAPTER NO. 15 : LATIN AMERICA OPIOID DRUGS MARKET – COUNTRY ANALYSIS

15.1. Latin America Opioid Drugs Market Overview By Country Segment

15.1.1. Latin America Opioid Drugs Market Revenue Share By Region

15.2. Latin America

15.2.1. Latin America Opioid Drugs Market Revenue By Country

15.2.2. Drug Class

15.2.3. Latin America Opioid Drugs Market Revenue By Drug Class

15.2.4. Application

15.2.5. Latin America Opioid Drugs Market Revenue By Application

15.2.6. Sales Channel

15.2.7. Latin America Opioid Drugs Market Revenue By Sales Channel

15.3. Brazil

15.4. Argentina

15.5. Rest of Latin America

CHAPTER NO. 16 : MIDDLE EAST OPIOID DRUGS MARKET – COUNTRY ANALYSIS

16.1. Middle East Opioid Drugs Market Overview By Country Segment

16.1.1. Middle East Opioid Drugs Market Revenue Share By Region

16.2. Middle East

16.2.1. Middle East Opioid Drugs Market Revenue By Country

16.2.2. Drug Class

16.2.3. Middle East Opioid Drugs Market Revenue By Drug Class

16.2.4. Application

16.2.5. Middle East Opioid Drugs Market Revenue By Application

16.2.6. Sales Channel

16.2.7. Middle East Opioid Drugs Market Revenue By Sales Channel

16.3. GCC Countries

16.4. Israel

16.5. Turkey

16.6. Rest of Middle East

CHAPTER NO. 17 : AFRICA OPIOID DRUGS MARKET – COUNTRY ANALYSIS

17.1. Africa Opioid Drugs Market Overview By Country Segment

17.1.1. Africa Opioid Drugs Market Revenue Share By Region

17.2. Africa

17.2.1. Africa Opioid Drugs Market Revenue By Country

17.2.2. Drug Class

17.2.3. Africa Opioid Drugs Market Revenue By Drug Class

17.2.4. Application

17.2.5. Africa Opioid Drugs Market Revenue By Application

17.2.6. Sales Channel

17.2.7. Africa Opioid Drugs Market Revenue By Sales Channel

17.3. South Africa

17.4. Egypt

17.5. Rest of Africa

CHAPTER NO. 18 : COMPANY PROFILES

18.1. Purdue Pharma L.P.

18.1.1. Company Overview

18.1.2. Product Portfolio

18.1.3. Financial Overview

18.1.4. Recent Developments

18.1.5. Growth Strategy

18.1.6. SWOT Analysis

18.2. Johnson & Johnson Services, Inc.

18.3. Hikma Pharmaceuticals PLC

18.4. Pfizer Inc.

18.5. AbbVie Inc.

18.6. Sanofi

18.7. Sun Pharmaceutical Industries Ltd

18.8. Grünenthal

18.9. Merck & Co., Inc.

18.10. Insys Therapeutics

18.11. Other Key Players

Request A Free Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Frequently Asked Questions:

What is the current market size for the Global Opioid Drugs Market, and what is its projected size in 2032?

The Global Opioid Drugs Market was valued at USD 15,712.5 million in 2018, reaching USD 22,518.0 million in 2024, and is projected to hit USD 38,293.0 million by 2032. The market shows strong growth due to rising demand for advanced pain management therapies across medical settings.

At what Compound Annual Growth Rate is the Global Opioid Drugs Market projected to grow between 2025 and 2032?

The Global Opioid Drugs Market is projected to grow at a CAGR of 6.92% between 2025 and 2032. It reflects steady expansion supported by rising healthcare investments and innovation in drug formulations.

Which Global Opioid Drugs Market segment held the largest share in 2024?

The pain management segment dominated in 2024, driven by high demand for chronic pain relief in oncology, orthopedics, and palliative care. Its clinical importance keeps it central to hospital and outpatient prescriptions.

What are the primary factors fueling the growth of the Global Opioid Drugs Market?

Key growth drivers include the rising prevalence of chronic pain disorders, post-surgical recovery needs, and expansion of palliative care services. Technological innovation in extended-release and safer opioid formulations also supports market growth.

Who are the leading companies in the Global Opioid Drugs Market?

Major companies include Purdue Pharma, Pfizer Inc., AbbVie Inc., Johnson & Johnson Services, Inc., Hikma Pharmaceuticals PLC, and Sanofi. These firms dominate through diversified drug portfolios and global distribution networks.

Who are the major players in this market?

Actavis Plc., Boehringer Ingelheim, Endo Pharmaceuticals Inc., Egalet, Janssen Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals Inc., Pfizer Inc., Purdue Pharma, Sanofi, and Sun Pharmaceutical Industries Ltd are some of the major players in the global market.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Related Reports

Bacterial Vaginosis Drugs Market

The Bacterial Vaginosis Drugs Market is projected to grow from USD 1,209.8 million in 2024 to an estimated USD 2,289.5 million by 2032, with a CAGR of 8.3% from 2024 to 2032.

Antitussives Market

The Antitussives Market is projected to grow from USD 1,417.2 million in 2024 to USD 2,038.66 million by 2032, with a CAGR of 4.65% from 2024 to 2032.

Medical Courier Market

Medical Courier Market size was valued at USD 6.75 Billion in 2024 and is anticipated to reach USD 10.36 Billion by 2032, at a CAGR of 5.5% during the forecast period.

Nuclear Medicine/ Radiopharmaceuticals Market

Nuclear Medicine/ Radiopharmaceuticals Market size was valued USD 7.43 Billion in 2024 and is anticipated to reach USD 13.44 Billion by 2032, at a CAGR of 7.7% during the forecast period.

Controlled Substance Market

The Controlled Substance Market size was valued at USD 93.68 Billion in 2024 and is anticipated to reach USD 139.89 Billion by 2032, at a CAGR of 5.14% during the forecast period.

Anti-Inflammatory Therapeutics Market

The Anti-Inflammatory Therapeutics Market size was valued at USD 105.73 Billion in 2024 and is anticipated to reach USD 144.25 Billion by 2032, at a CAGR of 3.96% during the forecast period.

Drug-Induced Immune Hemolytic Anemia Market

The drug induced immune hemolytic anemia market size was valued at USD 8258.65 million in 2024 and is anticipated to reach USD 12965.65 million by 2032, at a CAGR of 5.8 % during the forecast period.

H2-Receptor Antagonists Market

The H2 Receptor Antagonists Market was valued at USD 4.45 billion in 2024 and is projected to reach USD 6.78 billion by 2032, growing at a CAGR of 5.4% during the forecast period.

Wilson’s Disease Drugs Market

Wilson’s Disease Drugs market was valued at USD 655.2 million in 2024 and is anticipated to reach USD 856.13 million by 2032, growing at a CAGR of 3.4 % during the forecast period.

Real-Time Bioprocess Raman Analyzer Market

Real-Time Bioprocess Raman Analyzer Market size was valued USD 985.5 million in 2024 and is anticipated to reach USD 1693.27 million by 2032, at a CAGR of 7% during the forecast period.

Mantle Cell Lymphoma Treatment Market

The Global Mantle Cell Lymphoma Treatment Market was valued at USD 1,608.9 billion in 2018, increased to USD 2,212.7 billion in 2024, and is anticipated to reach USD 3,373.3 billion by 2032, growing at a CAGR of 5.42% during the forecast period.

Levothyroxine Sodium Market

Levothyroxine Sodium Market size was valued USD 4.27 billion in 2024 and is anticipated to reach USD 5.4 billion by 2032, at a CAGR of 3% during the forecast period.

Licence Option

Single User

$4999

Multi User

$6999

Enterprise

$12999

Report delivery within 24 to 48 hours

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Request A Free Sample

What people say?

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert

Trusted By

Request Sample